论文部分内容阅读
目的:观察加味龟鹿二仙胶汤对非小细胞肺癌(NSCLC)化疗患者免疫功能的影响。方法:选择晚期NSCLC住院患者75例,采用随机数字表法分为2组,对照组采用GP方案治疗,治疗组在对照组的基础上予加味龟鹿二仙胶汤。治疗4周为1疗程,连用3疗程后观察2组近期疗效、免疫功能、外周血象、重组人粒细胞集落刺激因子(G-CSF)使用率、KPS评分情况。结果:治疗后近期疗效稳定率治疗组为86.05%,对照组为62.50%,差异有显著性意义(P<0.05)。治疗后,治疗组CD4+、CD4+/CD8+比值、自然杀伤(NK)细胞活性均较治疗前有不同程度提高,差异均有显著性意义(P<0.05);治疗后,2组CD4+、CD8+、NK细胞活性分别比较,差异均有显著性意义(P<0.05)。治疗后,治疗组白细胞、血红蛋白、血小板减少发生率较低,与对照组比较,差异有显著性或非常显著性意义(P<0.05,P<0.01)。治疗组G-CSF使用率为16.3%,少于对照组的53.1%,差异有非常显著性意义(P<0.01)。治疗后治疗组KPS评分高于对照组,差异有显著性意义(P<0.05)。结论:加味龟鹿二仙胶汤能提高NSCLC化疗患者的免疫监视功能,减轻化疗的骨髓抑制,提高生活质量。
Objective: To observe the influence of Modified Guilu Erxian Decoction on immune function in patients with non-small cell lung cancer (NSCLC) chemotherapy. Methods: Seventy-five inpatients with advanced NSCLC were selected and divided into two groups by random number table. The control group was treated with GP regimen. The treatment group was treated with Guilu Erxian Decoction based on the control group. Treatment for 4 weeks for a course of treatment, once a course of 3 courses after treatment were observed two groups of short-term efficacy, immune function, peripheral blood, recombinant human granulocyte colony-stimulating factor (G-CSF) utilization, KPS score. Results: After treatment, the stability of the short term treatment group was 86.05%, while the control group was 62.50%, the difference was significant (P <0.05). After treatment, the ratio of CD4 +, CD4 + / CD8 + and natural killer (NK) cells in treatment group were significantly higher than those before treatment (P <0.05); After treatment, CD4 +, CD8 +, NK Cell activity were compared, the differences were significant (P <0.05). After treatment, the incidence of leukopenia, hemoglobin and thrombocytopenia in the treatment group was lower than that in the control group, and the difference was significant or very significant (P <0.05, P <0.01). The treatment group G-CSF utilization rate was 16.3%, less than 53.1% of the control group, the difference was significant (P <0.01). After treatment, KPS score of treatment group was higher than that of control group, the difference was significant (P <0.05). Conclusion: Modified Guilu Erxian Decoction can improve the immunosurveillance function of NSCLC chemotherapy patients, reduce the bone marrow suppression of chemotherapy and improve the quality of life.